Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects

Hypertension Research

Volumn 34, Issue 1, 2011, Pages 98-102

  Ito, Yuji ^a   Takeda, Ryoyu ^a   Karashima, Shigehiro ^b   Yamamoto, Yasuhiro ^b   Yoneda, Takashi ^b   Takeda, Yoshiyu ^b  

^a KKR Hokuriku Hospital   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

aldosterone; aldosteronism; prehypertension; primary; renin

Indexed keywords

ALDOSTERONE; CAPTOPRIL; EPLERENONE; POTASSIUM; RENIN; SPIRONOLACTONE;

ADRENALECTOMY; ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; JAPANESE; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PREHYPERTENSION; PREVALENCE; PRIMARY HYPERALDOSTERONISM; SCREENING TEST; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CAPTOPRIL; CHI-SQUARE DISTRIBUTION; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MALE; MASS SCREENING; MIDDLE AGED; PREHYPERTENSION; PREVALENCE; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 78650881516     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.166     Document Type: Article

References (28)

1. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol 2007; 66: 607-618.
2. Calhoun DA. Is there an unrecognized epidemic of primary aldosteronism? Hypertension 2007; 50: 447-453.
3. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young Jr WF. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85: 2854-2859.
4. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004; 27: 193-202.
5. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-896.
6. Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-165.
7. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-1867.
8. Vantyghem M-C, Ronci N, Provost F, Ghulam A, Lefebvre J, Jeunemaitre X, Tabarin A. Aldosterone-producing adenoma without hypertension: a report of two cases. Eur J Endocrinol 1999; 141: 279-285.
9. Medeau V, Moreau F, Trinquart L, Clemessy M, Wemeau J-L, Vantyghem M-C, Plouin P-F, Reznik Y. Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a comparison with hypertensive cases. Clin Endocrinol 2008; 69: 20-28.
10. Stowasser M, Bachmann AW, Huggard PR, Rossetti TR, Gordon RD. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. J Clin Endocrinol Metab 2000; 85: 2160-2166.
11. Williams JS, Williams GH, Raji A, Jeunemaitre X, Brown NJ, Hopkins PN, Conlin PR. Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. J Hum Hypertens 2006; 20: 129-136.
12. Nishizaka MK, Calhoun DA. Primary aldosteronism: diagnostic and therapeutic considerations. Curr Cardiol Rep 2005; 7: 412-417.
13. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572. (Pubitemid 37430158)
14. Rossi GP, Sacchetto A, Chiesura-Corona M, Toni RD, Gallina M, Feltrin P, Pessina AC. Identification of the etiology of aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 2001; 86: 1083-1090.
15. Matsunaga M, Hara A, Song TS, Hashimoto M, Tamori S, Ogawa K, Morimoto K, Pak CH, Kawai C, Yoshida O. Asymptomatic normotensive primary aldosteronism. Case report. Hypertension 1983; 5: 240-243.
16. Shiroto H, Ando H, Ebitani I, Hara M, Numazawa K, Kawamura S, Sasaki H. Normotensive primary aldosteronism. Am J Med 1980; 69: 603-606.
17. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281.
18. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello M-J, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F. PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300.
19. Umpierrez GE, Cantey P, Smiley D, Palacio A, Temponi D, Luster K, Chapman A. Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care 2007; 30: 1699-1703.
20. Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky Jr J. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the central Europe region. J Hum Hypertens 2003; 17: 349-352.
21. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33-41.
22. Dluhy RG, Williams GH. Aldosterone-villain or bystander? N Engl J Med 2004; 351: 8-10.
23. Ojeda NB, Grigore D, Robertson EB, Alexander BT. Estrogen protects against increased blood pressure in postpubertal female growth restricted offspring. Hypertension 2007; 50: 679-685.
24. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Palumbo G, Rizzoni D, Rossi E, Agabiti-Rosei E, Pessina AC, Mantero F. PAPY Study Investigators. Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension 2007; 50: 424-431. (Pubitemid 47205795)
25. Agharazii M, Douville P, Grose JH, Lebel M. Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension 2001; 37: 1440-1443.
26. Castro OL, Yu X, Kem DC. Diagnostic value of the post-captopril test in primary aldosteronism. Hypertension 2002; 39: 935-938.
27. Naomi S, Iwaoka T, Umeda T, Inoue J, Hamasaki S, Miura F, Fujii Y, Sato T. Clinical evaluation of the captopril screening test for primary aldosteronism. Jpn Heart J 1985; 26: 549-556.
28. Iwaoka T, Umeda T, Naomi S, Inoue J, Sasaki M, Yamauchi J, Sato T. The usefulness of the captopril test as a simultaneous screening for primary aldosteronism and renovascular hypertension. Am J Hypertens 1993; 6: 899-906.